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Annex 1  
 
 
  Extract from the Report of the 38th Expert Committee on 
Drug Dependence 
 
 
  Substances recommended to be scheduled in Schedule I of the Single 
Convention on Narcotic Drugs (1961), as amended by the 1972 
Protocol: 
 
 
  U-47700 
 
Chemically, U-47700 is 3,4-dichloro-N-(2-dimethylamino-cyclohexyl)-N-methyl-
benzamide. U-47700 has two chiral centres resulting in four isomers; cis and trans 
conformations each have two enantiomers [cis: are (1R,2R), and (1S,2S); trans are 
(1R,2S) and (1S,2R)]. 
U-47700 was not previously pre-reviewed or critically reviewed by the Committee. A 
direct critical review is proposed based on information brought to the attention of the 
WHO that U-47700 is clandestinely manufactured, poses risk to public health and 
society, and has no recognized therapeutic use by any Party. 
U-47700 (3,4-dichloro-N-(2-dimethylamino-cyclohexyl)-N-methyl-benzamide) is a 
compound liable to similar abuse and with similar ill-effects to controlled opioids such 
as morphine and AH-7921 that are included in Schedule I of the 1961 Single 
Convention on Narcotic Drugs. It has no recorded therapeutic use, and its use has 
resulted in fatalities. There is sufficient evidence that it is being or is likely to be 
abused so as to constitute a public health and social problem warranting the placing of 
the substance under international control. Thus, because it meets the required 
condition of similarity, it is recommended that U -47700 be placed in Schedule I of the 
Single Convention on Narcotic Drugs, 1961, as consistent with Article 3, paragraph 3 (iii) 
of that Convention in that the substance is liable to similar abuse and productive of 
similar ill-effects as drugs in Schedule I.  
 
  Butyrfentanyl 
 
Chemically, butyrfentanyl is N-phenyl-N-[1-(2-phenylethyl)-4-iperidinyl]butanamide.  
Butyrfentanyl has not been previously pre-reviewed or critically reviewed by the 
Committee. A direct critical review is proposed based on information brought to the 
attention of the WHO that butyrfentanyl is clandestinely manufactured, poses risk to 
public health and society, and has no recognized therapeutic use by any Party.  
Butyrfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]butanamide) is a 
compound liable to similar abuse and with similar ill-effects to controlled opioids such 
as morphine and fentanyl that are included in Schedule I of the 1961 Single 
Convention on Narcotic Drugs. It can be converted into fentanyl as well. It has no 
recorded therapeutic use and its use has resulted in fatalities. There is sufficient 
evidence that it is being or is likely to be abused so as to constitute a public health and 
social problem warranting the placing of the substance under international control. 
Thus, because it meets either of the required conditions of similarity or convertibility, 
it is recommended that butyrfentanyl be placed in Schedule I of the Single Convention 
on Narcotic Drugs, 1961, as consistent with Article 3, paragraph 3 (iii) of that 
Convention in that the substance is liable to similar abuse and productive of similar 
ill-effects as drugs in Schedule I. 
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  Substances recommended to be scheduled in Schedule II of the 
Convention on Psychotropic Substances (1971): 
 
 
  4-MEC (4-Methylethcathinone) 
 
Chemically, 4-methylethcathinone (4-MEC) is 2-(ethylamino)-1-(4-methylphenyl) 
propan-1-one. 4-MEC has a chiral centre giving rise to an enantiomeric pair of  
(S)-4-MEC and (R)-4-MEC isomers. 
A critical review report on 4-MEC was discussed in June 2014 at the 36th meeting of 
the WHO Expert Committee on Drug Dependence. The Committee recommended that 
4-MEC not be placed under international control at that time due to insufficiency of 
data regarding dependence, abuse and risks to public health, but be kept under 
surveillance. 4-MEC continues to appear as a psychostimulant with monoamine 
transporter activity with indications of abuse liability. New data have emerged from in 
vitro and in vivo studies since the 36th ECCD meeting that has prompted the current 
critical review. 
The Committee considered that the degree of risk to public health and society 
associated with the abuse of 4-MEC (2-(ethylamino)-1-(4-methylphenyl)propan-1-
one) is substantial. Therapeutic usefulness has not been recorded. It recognized that it 
has similar abuse and similar ill-effects as substances in Schedule II of the United 
Nations 1971 Convention on Psychotropic Substances. The Committee considered that 
there is sufficient evidence that 4-MEC is being or is likely to be abused so as to 
constitute a public health and social problem warranting the placing of the substa nce 
under international control. As per the Guidance on the WHO review of psychoactive 
substances for international control, higher regard was accorded to the substantial 
public health risk than to the lack of therapeutic usefulness. The Committee 
recommended that 4-MEC be placed in Schedule II under the United Nations 1971 
Convention on Psychotropic Substances.  
 
  Ethylone 
 
Chemically, ethylone is 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one. It 
is a chiral compound with isomers, and its hydrochloride salt can exist in two 
conformations (polymorphs) at the C-C bond linking the side chain to the aromatic 
ring. 
Ethylone was not previously pre-reviewed or critically reviewed. A direct critical 
review is proposed based on information brought to the attention of the WHO that 
ethylone is clandestinely manufactured, poses serious risk to public health and society, 
and has no recognized therapeutic use by any Party.  
The Committee considered that the degree of risk to public health and society 
associated with the abuse of ethylone (1-(2H-1,3-benzodioxol-5-yl)-2-
(ethylamino)propan-1-one) is substantial. Therapeutic usefulness has not been 
recorded. It recognized that it has similar abuse and similar ill -effects as substances in 
Schedule II of the United Nations 1971 Convention on Psychotropic Substances. The 
Committee considered that there is sufficient evidence that ethylone is being or is 
likely to be abused so as to constitute a public health and social problem warranting 
the placing of the substance under international control. As per the Guidance on the 
WHO review of psychoactive substances for international control , higher regard was 
accorded to the substantial public health risk than to the lack of therapeutic usefulness. 
The Committee recommended that ethylone be placed in Schedule II under the United 
Nations 1971 Convention on Psychotropic Substances.  
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  Pentedrone (α-Methylaminovalerophenone) 
 
Chemically, pentedrone is 2-(methylamino)-1-phenylpentan-1-one. It has a chiral 
centre giving rise to two stereoisomers, (S)- and (R)- pentedrone. 
Pentedrone has not been previously reviewed or critically reviewed by the Expert 
Committee on Drug Dependence of the WHO. A direct critical review is proposed 
based on information brought to WHO’s attention that pentedrone is  clandestinely 
manufactured, poses serious risk to public health and society, and has no recognized 
therapeutic use by any Party.  
The Committee considered that the degree of risk to public health and society 
associated with the abuse of pentedrone (2-(methylamino)-1-phenylpentan-1-one) is 
substantial. Therapeutic usefulness has not been recorded. It recognized that it has 
similar abuse and similar ill-effects as substances in Schedule II of the United Nations 
1971 Convention on Psychotropic Substances. The Committee considered that there is 
sufficient evidence that pentedrone is being or is likely to be abused so as to constitute 
a public health and social problem warranting the placing of the substance under 
international control. As per the Guidance on the WHO review of psychoactive 
substances for international control, higher regard was accorded to the substantial 
public health risk than to the lack of therapeutic usefulness. The Committee 
recommended that pentedrone be placed in Schedule II under the United Nations 1971 
Convention on Psychotropic Substances.  
 
  Ethylphenidate (EPH) 
 
Chemically, ethylphenidate is ethyl phenyl(piperidin-2-yl)acetate.  
Ethylphenidate was not previously pre-reviewed or critically reviewed. A direct 
critical review is proposed based on information brought to the attention of the WHO 
that ethylphenidate is clandestinely manufactured, poses serious risk to public health 
and society, and has no recognized therapeutic use by any Party.  
The Committee considered that the degree of risk to public health and society 
associated with the abuse of ethylphenidate (ethyl phenyl(piperidin -2-yl)acetate) is 
substantial. Therapeutic usefulness has not been recorded. It recognized that it has 
similar abuse and similar ill-effects as substances in Schedule II of the United Nations 
1971 Convention on Psychotropic Substances. The Committee considered that there is 
sufficient evidence that ethylphenidate is being or is likely to be abused so as to 
constitute a public health and social problem warranting the placing of the substance 
under international control. As per the Guidance on the WHO review of psychoactive 
substances for international control, higher regard was accorded to the substantial 
public health risk than to the lack of therapeutic usefulness. The Committee 
recommended that ethylphenidate be placed in Schedule II under the United Nations 
1971 Convention on Psychotropic Substances.  
 
  MPA (Methiopropamine) 
 
Chemically, methiopropamine is N-methyl-1-(thiophen-2-yl)propan-2-amine. It has a 
chiral centre with two enantiomers.  
Methiopropamine was previously critically reviewed by the Committee at its  
36th meeting. Owing to the insufficiency of data regarding dependence, abuse and 
risks to public health, the Committee recommended that methiopropamine not be 
placed under international control but be kept under surveillance. Subsequent data 
collected from the literature and from different countries indicated that this substance 
may cause substantial harm and that it has no medical use warranting an updated 
critical review. 
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The Committee considered that the degree of risk to public health and society 
associated with the abuse of methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-
amine) is substantial. Therapeutic usefulness has not been recorded. It recognized that 
it has similar abuse and similar ill-effects as substances in Schedule II of the United 
Nations 1971 Convention on Psychotropic Substances. The Committee considered that 
there is sufficient evidence that methiopropamine is being or is  likely to be abused so 
as to constitute a public health and social problem warranting the placing of the 
substance under international control. As per the Guidance on the WHO review of 
psychoactive substances for international control , higher regard was accorded to the 
substantial public health risk than to the lack of therapeutic usefulness. The 
Committee recommended that methiopropamine be placed in Schedule II under the 
United Nations 1971 Convention on Psychotropic Substances.  
 
  MDMB-CHMICA 
 
Chemically, MDMB-CHMICA is methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-
yl]carbonyl}-3-methyl-L-valinate. MDMB-CHMICA has a chiral carbon in the 
butanoic chain. Therefore, two stereoisomers exist: (S)-MDMB-CHMICA and  
(R)-MDMB-CHMICA.  
MDMB-CHMICA has not been previously pre-reviewed or critically reviewed. A 
direct critical review is proposed based on information brought to the attention of the 
WHO that MDMB-CHMICA is clandestinely manufactured, poses serious risk to 
public health and society, and has no recognized therapeutic use by any Party. 
The Committee considered that the degree of risk to public health and society 
associated with the abuse of MDMB-CHMICA (methyl N-{[1-(cyclohexylmethyl)-1H-
indol-3-yl]carbonyl}-3-methyl-L-valinate) is substantial. Therapeutic usefulness has 
not been recorded. It recognized that it has similar abuse and similar ill -effects as 
substances in Schedule II of the United Nations 1971 Convention on Psychotropic 
Substances. The Committee considered that there is sufficient evidence that  
MDMB-CHMICA is being or is likely to be abused so as to constitute a public health 
and social problem warranting the placing of the substance under international control. 
As per the Guidance on the WHO review of psychoactive substances for international 
control, higher regard was accorded to the substantial public health risk than to the 
lack of therapeutic usefulness. The Committee recommended that MDMB -CHMICA 
be placed in Schedule II under the United Nations 1971 Convention on Psychotropic 
Substances. 
 
  5F-APINACA (5F-AKB-48) 
 
Chemically, 5F-APINACA is N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide.  
5F-APINACA has not been previously pre-reviewed or critically reviewed by the 
Expert Committee on Drug Dependence of WHO. A direct critical review is proposed 
based on information brought to the attention of the WHO that 5F-APINACA is 
clandestinely manufactured, poses serious risk to public health and society, and has no 
recognized therapeutic use by any Party.  
The Committee considered that the degree of risk to public health and society 
associated with the abuse of 5F-APINACA (N-(adamantan-1-yl)-1-(5-fluoropentyl)-
1H-indazole-3-carboxamide) is substantial. Therapeutic usefulness has not been 
recorded. It recognized that it has similar abuse and similar ill -effects as substances in 
Schedule II of the United Nations 1971 Convention on Psychotropic Substances. The 
Committee considered that there is sufficient evidence that 5F -APINACA is being or 
is likely to be abused so as to constitute a public health and social problem warranting 
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the placing of the substance under international control. As per the Guidance on the 
WHO review of psychoactive substances for international control , higher regard was 
accorded to the substantial public health risk than to the lack of therapeutic usefulness. 
The Committee recommended that 5F-APINACA be placed in Schedule II under the 
United Nations 1971 Convention on Psychotropic Substances.  
 
  XLR-11 
 
Chemically,  XLR-11 is [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) 
methanone.  
XLR-11 has not been previously pre-reviewed or critically reviewed. A direct critical 
review is proposed based on information brought to WHO’s attention that XLR -11 is 
clandestinely manufactured, poses serious risk to public health and society, and has no 
recognized therapeutic use by any Party.  
The Committee considered that the degree of risk to public health and society 
associated with the abuse of XLR-11 ([1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone) is substantial. Therapeutic usefulness has not been 
recorded. It recognized that it has similar abuse and similar ill-effects as substances in 
Schedule II of the United Nations 1971 Convention on Psychotropic Substances such 
as JWH-018 and AM-2201. The Committee considered that there is sufficient evidence 
that XLR-11 is being or is likely to be abused so as to constitute a public health and 
social problem warranting the placing of the substance under international control. As 
per the Guidance on the WHO review of psychoactive substances for international 
control, higher regard was accorded to the substantial public health risk than to the 
lack of therapeutic usefulness. The Committee recommended that XLR -11 be placed 
in Schedule II under the United Nations 1971 Convention on Psychotropic Substances.  
 
 
  Substance recommended for critical review: 
 
 
  3-Methylmethcathinone (3-methyl-N-methylcathinone; 3-MMC) 
 
Chemically, 3-MMC is 2-(methylamino)-1-(3-methylphenyl)propan-1-one. 3-MMC 
contains a chiral centre at the C-2 carbon of the propane sidechain, so two enantiomers 
exist: (R)-3-MMC and (S)-3-MMC. 
3-MMC was not previously pre-reviewed or critically reviewed. A direct critical 
review is proposed based on information brought to the attention of the WHO that  
3-MMC is clandestinely manufactured, poses serious risk to public health and society, 
and has no recognized therapeutic use by any Party.  
The Committee deliberated at length regarding the information available pertinent to 
the degree of risk to public health and society associated with the abuse of 3 -MMC  
(2-(methylamino)-1-(3-methylphenyl)propan-1-one). The Committee decided that the 
information as currently provided, and the ensuing discussions that had occurred, were 
inadequate to form a consensus and confident recommendation regarding the 
scheduling of 3-MMC. As per paragraph 59 of the Guidance on the WHO review of 
psychoactive substances for international control , and as supported by its procedural 
reference to the Thirty-fourth report of the WHO Expert Committee on Drug 
Dependence, “... in cases where additional information concerning the substance under 
review is required, the Committee may decide that it will reach a final opinion at a 
subsequent meeting.” “... then it should request another critical review in order to refer 
the matter to a subsequent Expert Committee.” As directed by these guidelines, the 
Committee requested that the Secretariat arrange another critical review of 3 -MMC at 
a subsequent Expert Committee. 
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  Substance recommended for surveillance: 
 
 
  JWH-073 
 
Chemically, JWH-073 is (1-butyl-1H-indol-3-yl)(1-naphthyl)methanone.  
During its 36th meeting, the WHO Expert Committee on Drug Dependence discussed 
the critical review report on JWH-073 and concluded that owing to the current 
insufficiency of data regarding dependence, abuse and risks to public health, JWH -073 
should not be placed under international control at that time but be kept under 
surveillance. New information on its pharmacology and abuse potential warranted an 
update of the critical review report for discussion at the 38th ECDD.  
The available pharmacodynamic data related to JWH-073 (1-butyl-1H-indol-3-yl) 
(1-naphthyl)methanone) demonstrates that this substance has the capacity to produce 
some effects similar to its homologue, JWH-018, that is included in Schedule II of the 
United Nations 1971 Convention on Psychotropic Substances. However, the data 
currently available does not make it possible to establish a direct link between  
JWH-073 abuse and appearance of public health and social problems that would be a 
requirement for placing this substance under international control. It is therefore 
recommended not to place JWH-073 under international control but to continue to 
keep it under surveillance. 
 
 
  Update on cannabis and cannabis resin: 
 
 
At the 37th ECDD meeting the Committee requested that Secretariat begin collecting 
data towards a pre-review of cannabis, cannabis resin, extracts and tinctures of 
cannabis at a future meeting. Consistent with this request, two updates on the 
scientific literature on cannabis were prepared and subsequently presented to the 
Expert Committee. Following its deliberations the Committee noted that the current 
Schedule I of the 1961 Convention groups together cannabis and cannabis resin, 
extracts and tinctures of cannabis. Cannabis plant and cannabis resin are also in 
Schedule IV of the 1961 Convention. The Committee further noted that there are 
natural and synthetic cannabinoids in Schedule I and Schedule II of the 1971 
Convention. The committee recognized:  
 - An increase in the use of cannabis and its components for medical purposes  
 - The emergence of new cannabis-related pharmaceutical preparations for 
therapeutic use 
 - Cannabis has never been subject to a formal pre-review or critical review by 
the ECDD.  
The Committee requested that the Secretariat prepare relevant documentation in 
accordance with the Guidance on the WHO review of psychoactive substances for 
international control in order to conduct pre-reviews for the following substances:  
 - Cannabis plant and cannabis resin 
 - Extracts and tinctures of cannabis 
 - Delta-9-tetrahydrocannabinol (THC) 
 - Cannabidiol (CBD) 
 - Stereoisomers of THC. 
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The Committee recommended that these pre-reviews be evaluated at a specific ECDD 
meeting dedicated to cannabis and its component substances to be held within the next 
eighteen months from the 38th meeting.  
The purpose of the pre-review is to determine whether current information justifies an 
Expert Committee critical review. The categories of information for evaluat ing 
substances in pre-reviews are identical to those used in critical reviews. The  
pre-review is a preliminary analysis, and findings at this stage should not determine 
whether the control status of a substance should be changed.  
 
